Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TPTH will it replace NPTH in portfolio? -- Ignore unavailable to you. Want to Upgrade?

To: Joseph Ziebarth who wrote (6)	2/1/2002 1:02:51 AM
From: Donald L. York	Read Replies (1) \| Respond to of 8

I have hopes for the success of TPTH. I am in the field and see many laboratories moving from the competitor product (CYTC, first out and aggressively marketed). I feel the technology is better and now with Autopap screening approved I think you will see many large laboratories moving to TriPath Autocyte technology as a package deal with the PREP instrument and computer screening. It's a good product, company, and ultimately benefits the patient.